Aridis shares plunge ~25% as antibody drug fails Phase 3 trial in pneumonia
gorodenkoff Aridis Pharmaceuticals (NASDAQ:ARDS) AR-301 monoclonal antibody therapy failed the primary endpoint in a phase 3 trial to treat ventilator-associated ...
gorodenkoff Aridis Pharmaceuticals (NASDAQ:ARDS) AR-301 monoclonal antibody therapy failed the primary endpoint in a phase 3 trial to treat ventilator-associated ...